Cabaletta Bio, Inc.
CABA · XNASCIK 1759138fmd_0HQNR72BC1MTBVH1Y3G1RV0T4CManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 34 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Research and development | 4 | 12 | 21 | 32 | 39 | 55 | 97 | 143 |
| Total operating expenses | 6 | 19 | 34 | 46 | 54 | 75 | 125 | 172 |
| Operating income | (6) | (19) | (34) | (46) | (54) | (75) | (125) | (172) |
| Interest expense | – | – | – | – | – | 0 | 1 | 2 |
| Interest and investment income | 0 | 2 | 0 | 0 | 1 | 7 | 10 | 6 |
| Income tax expense | – | – | – | – | – | – | 0 | 0 |
| Net income | (12) | (17) | (33) | (46) | (53) | (68) | (116) | (168) |
| Net income to common shareholders | (12) | (22) | (33) | – | – | – | – | – |